Camlin Fine Sciences Ltd Q1 FY26 – Revenues ₹424 Cr, Loss ₹-3.9 Cr, P/E at 111x. Chemicals, Court Cases & Cash Crunch in One Beaker.
1. At a Glance
CMP ₹224, market cap ₹4,205 Cr. Stock P/E? 111x. Yes, you read that right — a loss-making company still sells dreams more expensive than Pidilite’s Fevicol. Book value ₹48, so P/B 4.67. ROE a stylish -15% (negative returns dressed as “future potential”). Debt ₹681 Cr, D/E 0.76. OPM 10.4%, but PAT margin last year -9%.
Past year return = +118% (thank you, chemical bull run). Last 3 months = -31% (thank you, reality check). Investors who thought they bought antioxidants for their portfolio ended up with acid reflux.
2. Introduction
Camlin Fine Sciences (CFS) sells itself as the “guardian of shelf life.” Basically, they make antioxidants, preservatives, and specialty chemicals that keep food, feed, and fuel from going bad. The irony? Their own financials have aged faster than curd left in the sun.
Exports form 85% of revenue, so it’s a global player in name. But execution? Italy plant shut in 2023, Gujarat plant received closure orders in 2025, subsidiary in Guatemala reported a ₹6.08 Cr employee fraud, and their Chinese JV partner got slammed with a ₹180 Cr penalty.
The market keeps them in the “specialty chemicals” basket (a sexy label since 2020), but reality is messy: lumpy cash flows, high debt, low coverage, governance red flags, and promoters pledging ~11% stake. Yet traders can’t resist — it’s that toxic ex you keep going back to.
3. Business Model – WTF Do They Even Do?
Camlin Fine = chemicals buffet:
Shelf-Life Solutions (72% revenue) – Antioxidants like TBHQ, BHA, ASP (they control ~50% of India’s market). – Custom blends (“NaSure” clean-label solutions). Basically, keeping chips crunchy and chicken feed mold-free.
Performance Chemicals (26%) – HQ derivatives (MEHQ, HQEE, Chloranil). – CT derivatives (Guaiacol, Veratrole). – Lockheed Martin is a customer for specialty chemical derivatives used in energy storage. Yes, from poultry feed to Pentagon projects.
Aroma Ingredients (2%) – Vanillin, ethyl vanillin (flavor of ice cream). Fully integrated via catechol route. Problem? Chinese players dump cheaper.
Health & Wellness (tiny) – Omega-3 from algae via AlgaIR NutraPharms. Sounds futuristic, contributes negligible.
Global spread: 1,250+ customers across 160 countries. Names include Shell, Cargill, Adani Wilmar. But also names include “closure orders” and “fraud reports.”
Question: Would you pay 111x P/E for a company that preserves chicken feed but can’t preserve its own bottom line?
4. Financials Overview
Q1 FY26
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹424 Cr
₹381 Cr
₹437 Cr
11.2%
-3%
EBITDA
₹19 Cr
₹29 Cr
₹59 Cr
-34%
-68%
PAT
-₹3.96 Cr
₹12 Cr
₹0 Cr
-133%
—
EPS (₹)
-0.53
0.83
-0.04
N.M.
N.M.
Annualised EPS = negative → P/E not meaningful (but market shows 111x as if this were Pidilite 2.0).
Auditor commentary: Revenue growth okay, profitability evaporated like alcohol in lab beakers.
5. Valuation Discussion – Fair Value Range
a) P/E Method EPS FY25 = -₹6.12 → P/E useless.
b) EV/EBITDA Method EV ₹4,733 Cr, EBITDA FY25 ~₹220 Cr → EV/EBITDA ~21.5x. Peers
